Aclaris Therapeutics (ACRS) Asset Writedowns and Impairment (2023)
Aclaris Therapeutics' (ACRS) quarterly Asset Writedowns and Impairment came in at $6.6 million in Q4 2023.
Aclaris Therapeutics (ACRS) Asset Writedowns and Impairment (2023) Analysis & Trends
Aclaris Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $6.6 million for Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - |
| 10 | Aclaris Therapeutics | 714.90 Mn | 609.48 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.60 Mn |
| Dec 31, 2023 | 6.60 Mn |